| Autor: |
Liane, Hoefferer, Isabelle, Glauser, Annette, Gaida, Katharina, Willimann, Adriano, Marques Antunes, Brigitte, Siani, Sandra, Wymann, Eleonora, Widmer, Ibrahim, El Menyawi, Reinhard, Bolli, Martin, Spycher, Martin, Imboden |
| Rok vydání: |
2015 |
| Předmět: |
|
| Zdroj: |
Transfusion. 55 |
| ISSN: |
1537-2995 |
| Popis: |
The passive transfer of antibodies specific to blood groups A and B (also called isoagglutinins) contained in immunoglobulin (Ig)G products for intravenous administration (IVIG) is believed to be largely responsible for rare but sometimes serious IVIG-related hemolytic events. We present in this work a modification of the manufacturing process of Privigen-a 10% l-proline-stabilized IVIG product-that allows extensive reduction of isoagglutinin concentrations in the final product.An additional immunoaffinity chromatography (IAC) step was introduced toward the end of the manufacturing process of Privigen. Isoagglutinin titers were measured using the indirect agglutination method and a published flow cytometry-based binding assay. Quality attributes, such as microorganism counts and concentration of endotoxins, IgG, IgA, IgM, aggregates, and so forth were measured using standardized procedures.The introduction of an IAC step in the manufacturing process of Privigen resulted in an 88% to 90% reduction in isoagglutinins between the feed of the chromatography column and the flow-through fraction. All other product quality attributes measured were nearly identical before and after IAC. This process modification resulted in a three-titer-step reduction in isoagglutinin levels in the final IgG product compared to Privigen lots produced by the unmodified process.Introducing an isoagglutinin-specific IAC step in the manufacturing process of Privigen is an efficient strategy for reduction of anti-A and anti-B titers. Such reductions might help minimize the risk of hemolytic events in patients receiving IVIG therapy. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Plný text